Rob Fox | Head of EU Business Development
IDIS, a Clinigen Company

Rob Fox, Head of EU Business Development, IDIS, a Clinigen Company

Rob works within the global business development team consulting with pharmaceutical and biotech companies to identify and implement strategic solutions to meet their global access needs. 
With more than 13 years experience in managed access programmes; he has worked across a range of therapeutic areas including oncology, critical care, HIV and orphan diseases.  In co-ordination with our regulatory, medical and operations teams, he has initiated and delivered more than 50 access programmes on behalf of our partners and is an expert in the complexities of global access throughout a product’s lifecycle. 
He earned a BA honours degree in business economics from the University of Liverpool.


Day 1 Orphan 14th Nov @ 15:15

Early access to orphan medicines – a glimpse into the future

  • Current market trends and key predictions over next 5 years in relation to how pharma and biotech companies will plan for and enable successful early access that compliments and forms part of their market access strategy

back to speakers